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Abstract
With great interest, I read the paper of David J. Dries about recent developments, infection control
and outcomes research in the management of burn injuries [1]. I have some comments about an
important, however missing, topic in the paragraphs concerning infection control.
Dear Sir,
With great interest, I read the paper of David J. Dries about
recent developments, infection control and outcomes
research in the management of burn injuries [1]. I have
some comments about an important, however missing,
topic in the paragraphs concerning infection control.
Infectious complications and sepsis are still the most
important reasons of mortality in burn centres. Therefore,
not only bacterial infections should be considered as the
source of infection. Fungal colonization and infection
gain a rising importance in the management of sepsis in
burn patients. Burn patients are at the highest risk for
mycoses, even more than oncologic and transplant
patients [2]. Due to compromised immune defence and
large wound surfaces, burn patients are predisposed for
acquiring fungal organisms. The broad use of topic and
systemic antibiotic agents either as prophylaxis or in case
of confirmed bacterial infection further facilitates the
development of mycoses.
Recently, a certain dynamic in the epidemiology of fungal
organisms has been observed. Non-albicans Candida spe-
cies have been found to be increasingly resistant against
common antimycotic substances. Additionally, other spe-
cies such as Aspergillus and Zygomycoses, with an aggres-
sive and invasive growth pattern are more frequently
observed. The diagnostic methods to indentify mycoses
are still poor and often specific to some organisms. Direct
tissue biopsy is performed rarely and mostly in case of a
justified suspicion. The growth of fungal cultures is unre-
liable and associated with considerable latency - some-
times too late for the clinician to initiate antimycotic
therapy appropriately. Since burn patients usually present
with SIRS symptoms, clinical warning signals may be
masked or misleading to bacterial infection. The author
correctly highlights the need for a re-evaluation of defini-
tions of SIRS and sepsis, as previously published [3].
Risk factors for acquiring a fungal infection are greater
burned total body surface area, increasing age, late surgi-
cal excision, central venous catheters, hyperglycaemic epi-
sodes, steroid treatment, long-term artificial ventilation
and inhalation injury. Mortality of mycotic burn patients
is associated with i.v.-antimycotics, the presence of fun-
gaemia, multiple positive cultures and invasion of healthy
skin [2,4,5]. Although there exist no randomized control-
led trials to initiate a timely antimycotic prophylaxis in
burn patients, a lower threshold may decrease the risk of
fatal fungal sepsis. Contra-arguments may be the possible
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development of antimycotic resistances and increasing
costs.
Available antimycotic substances such as echinocandins
and triazoles show advantages compared to classic imida-
zol-based azoles and polyenes concerning efficacy, specif-
ity, toxicity profile and patient comfort. Promising results
are to be expected by candida-secretoric aspartic proteases
(SAPs) inhibitors and calcineurin signaling pathway
blockers [6].
However, despite the introduction of new antimycotic
substances, some fungal organisms preserving angioinva-
sive and proteolytic potential, still require radical surgical
therapy to provide a chance for survival. The restoration of
immune resistance, early surgical therapy and early
wound closure gain a key function in limiting the risk of
fungal infection in burn patients [2,3,5].
Fungal infections should not be underestimated in mod-
ern burn care.
Abbreviations
SAPs: secretoric aspartic proteases; SIRS: severe inflamma-
tory response syndrome
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